Research ArticleArticle
Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry
Vivian P. Bykerk, Nancy Shadick, Michelle Frits, Clifton O. Bingham III, Iain Jeffery, Christine Iannaccone, Michael Weinblatt and Daniel H. Solomon
The Journal of Rheumatology December 2013, jrheum.121521; DOI: https://doi.org/10.3899/jrheum.121521
Vivian P. Bykerk
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Nancy Shadick
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Michelle Frits
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Clifton O. Bingham III
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Iain Jeffery
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Christine Iannaccone
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Michael Weinblatt
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
Daniel H. Solomon
From the Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School, New York, New York; Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts; Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland; Touro College of Osteopathic Medicine, New York, New York, USA. The BRASS Cohort Study was designed and implemented by the investigators and financially supported by Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Biosciences. Dr. Bykerk has received research grants and/or served as a consultant to Abbott Laboratories, Amgen, Astellas, Antares, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen Biotech, Pfizer, Roche/Genentech, and UCB not related to this study. Dr. Shadick has received research funding from Crescendo Biosciences, Medimmune, Amgen, Genentech, and Abbott. Dr. Bingham has received research grants and/or served as a consultant to Abbott, Amgen, BMS, Celgene, Genentech/Roche, Janssen/Johnson and Johnson/Centocor, Pfizer, and UCB. Dr. Weinblatt has received funding for BRASS from Biogen/Idec, Bristol Myers Squibb, and Medimmune Crescendo Bioscience and serves as a consultant to them. Dr. Solomon has received research grants from Amgen and Lilly for work unrelated to this article. He has also served in unpaid roles on trials sponsored by Novartis, Pfizer, Bristol Myers Squibb, and Lilly. V.P. Bykerk, MD, Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical School; N. Shadick, MD, MPH; M. Frits, BA, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital; C.O. Bingham III, MD, Division of Rheumatology, Johns Hopkins University; I. Jeffery, D.O. Candidate, Touro College of Osteopathic Medicine; C. Iannaccone, MPH; M. Weinblatt, MD; D.H. Solomon, MD, MPH, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital. Address correspondence to Dr. V.P. Bykerk, Department of Rheumatology, Hospital for Special Surgery, 535 East 70th St., New York, New York 10021, USA. E-mail: bykerkv@hss.edu. Accepted for publication September 27, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry
Vivian P. Bykerk, Nancy Shadick, Michelle Frits, Clifton O. Bingham , Iain Jeffery, Christine Iannaccone, Michael Weinblatt, Daniel H. Solomon
The Journal of Rheumatology Dec 2013, jrheum.121521; DOI: 10.3899/jrheum.121521
Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry
Vivian P. Bykerk, Nancy Shadick, Michelle Frits, Clifton O. Bingham , Iain Jeffery, Christine Iannaccone, Michael Weinblatt, Daniel H. Solomon
The Journal of Rheumatology Dec 2013, jrheum.121521; DOI: 10.3899/jrheum.121521